67.
Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solo-
mon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle
D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner
JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR,
Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B,
Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Inves-
tigators. Celecoxib for the prevention of sporadic colorectal
adenomas. N Engl J Med 2006;355:873-84.
68.
Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavo-
ral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB,
Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG,
Solomon SD, Levin B; PreSAP Trial Investigators. Celeco-
xib for the prevention of colorectal adenomatous polyps. N
Engl J Med 2006;355:885-95.
69.
Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, La-
nas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Mor-
ton DG; APPROVe Trial Investigators. A randomized trial
of rofecoxib for the chemoprevention of colorectal adeno-
mas. Gastroenterology 2006;131:1674-82.
70.
Routine aspirin or nonsteroidal anti-inflammatory drugs for
the primary prevention of colorectal cancer: U.S. Preventive
Services Task Force recommendation statement. Ann Intern
Med 2007;146:361.
71.
Rich M, Scheiman JM. Nonsteroidal anti-inflammatory
drug gastropathy at the new millennium: mechanisms and
prevention. Semin Arthritis Rheum 2000;30:167-79.
72.
Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal to-
xicity of nonsteroidal antiinflammatory drugs. N Engl J
Med 1999;340:1888-1899.
73.
Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fri-
es JF.. Gastrointestinal tract complications of nonsteroidal
anti-inflammatory drug treatment in rheumatoid arthritis.
A prospective observational cohort study. Arch Intern Med
1996;156:1530-6.
74.
Flower R. The development of COX2 inhibitors. Nat Rev
Drug Discov 2003;2:179.
75.
Estes LL, Fuhs DW, Heaton AH, Butwinick CS. Gastric ul-
cer perforation associated with the use of injectable ketoro-
lac. Ann Pharmacother 1993;27:42-3.
76.
Wolfe PA, Polhamus CD, Kubik C, Robinson AB, Clement
DJ. Giant duodenal ulcers associated with the postoperative
use of ketorolac: report of three cases. Am J Gastroenterol
1994;89:1110-1.
77.
Cryer, B, Feldman, M. Cyclooxygenase-1 and cyclooxygena-
se-2 selectivity of widely used nonsteroidal anti-inflamma-
tory drugs. Am J Med 1998;104:413.
78.
Jick H. Effects of aspirin and acetaminophen in gastrointes-
tinal hemorrhage. Arch Intern Med 1981;141:316.
79.
Blot, WJ, McLaughlin, JK. Over the counter non-steroidal
anti-inflammatory drugs and risk of gastrointestinal blee-
ding. J Epidemiol Biostat 2000;5:137.
80.
Lanza, FL, Codispoti, JR, Nelson, EB. An endoscopic com-
parison of gastroduodenal injury with over-the-counter do-
ses of ketoprofen and acetaminophen. Am J Gastroenterol
1998;93:1051.
81.
Takeuchi K, Yasuhiro T, Asada Y, Sugawa Y. Role of nitric
oxide in pathogenesis of aspirin-induced gastric mucosal da-
mage in rats. Digestion 1998;59:298-307.
82.
Jimenez D, Martin MJ, Pozo D, Alarcon C, Esteban J, Bru-
seghini L, Esteras A, Motilva V. Mechanisms involved in
protection afforded by L-arginine in ibuprofen-induced gas-
tric damage: role of nitric oxide and prostaglandins. Dig Dis
Sci 2002;47:44-53.
83.
Richy F, Bruyere O, Ethgen O, Rabenda V, Bouvenot G,
Audran M, Herrero-Beaumont G, Moore A, Eliakim R, Ha-
im M, Reginster JY. Time dependent risk of gastrointesti-
nal complications induced by non-steroidal anti-inflamma-
tory drug use: a consensus statement using a meta-analytic
approach. Review. Ann Rheum Dis 2004;63:759-66.
84.
Laine L, Bombardier C, Hawkey CJ, Davis B, Shapiro D,
Brett C, Reicin A. Stratifying the risk of NSAID-related
upper gastrointestinal clinical events: results of a double-
blind outcomes study in patients with rheumatoid arthritis.
Gastroenterology 2002;123:1006-12.
85.
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T,
Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson
WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Ver-
burg KM, Geis GS. Gastrointestinal toxicity with celecoxib
vs nonsteroidal anti-inflammatory drugs for osteoarthritis
and rheumatoid arthritis: the CLASS study: A randomized
controlled trial. Celecoxib Long-term Arthritis Safety
Study. JAMA 2000;284:1247-55.
86.
Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Do-
herty M, Ehrsam E, Gitton X, Krammer G, Mellein B,
Matchaba P, Gimona A, Hawkey CJ. TARGET Study Gro-
up.Comparison of lumiracoxib with naproxen and ibuprofen
in the Therapeutic Arthritis Research and Gastrointestinal
Event Trial (TARGET), reduction in ulcer complications:
randomised controlled trial. Lancet 2004;364(9435):665-
74.
87.
Laine L, Curtis SP, Cryer B, Kaur A, Cannon CP; MEDAL
Steering Committee. Assessment of upper gastrointestinal
safety of etoricoxib and diclofenac in patients with osteoart-
hritis and rheumatoid arthritis in the Multinational Etori-
coxib and Diclofenac Arthritis Long-term (MEDAL) prog-
ramme: a randomised comparison. Lancet 2007;369(9560):
465-73.
88.
Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of
valdecoxib for treatment of osteoarthritis and rheumatoid
arthritis: systematic review of randomised controlled trials.
Pain 2004;111(3):286-96.
89.
Rostom A, Muir K, Dubé C, Jolicoeur E, Boucher M, Joyce
J, Tugwell P, Wells GW Gastrointestinal safety of cyclo-
oxygenase-2 inhibitors: a cochrane collaboration systematic
review. Clin Gastroenterol Hepatol 2007;5(7):818-28.
90.
Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge
WE. The impact of low-dose aspirin on endoscopic gastric
and duodenal ulcer rates in users of a non-selective non-ste-
799
BÖLÜM 52
n
Basit Analjezikler ve Steroid Olmayan Antiinflamatuvar